Skip to main content
LISATA THERAPEUTICS, INC. logo

LISATA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LSTA ISIN · US1280583022 LEI · 5493002287F62M3EGQ04 US Manufacturing
Open in API
Filings indexed 1,093 across all filing types
Latest filing 2013-05-09 Interim / Quarterly Rep…
Country US United States of America
Listing US LSTA

About LISATA THERAPEUTICS, INC.

https://www.lisata.com/

Lisata Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for advanced solid tumors and other major diseases. The company's core technology is the proprietary CendR Platform®, designed to enhance the targeted, tissue-penetrating delivery of anti-cancer drugs to solid tumors. The platform also aims to target non-cancerous, immunosuppressive cells within the tumor microenvironment, seeking to improve the efficacy of a patient's immune system and immunotherapies in fighting cancer.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2013
2013-05-09 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated April 30, 2013, for NeoStem, Inc. The content focuses on announcements related to a public offering of common stock and the partial exercise of an over-allotment option by the underwriter. There are no financial statements or detailed financial data included, only a press release about financing activities. The document length is 2669 characters, which is relatively short and primarily serves as an announcement of financing events. This fits the category of Capital/Financing Update (CAP) rather than a full financial report or other categories.
2013-05-01 English
424B2
Capital/Financing Update Classification · 95% confidence The document is a 'Final Prospectus Supplement' filed pursuant to Rule 424(b)(2) with the SEC, related to an offering of 20,000,000 shares of common stock. It includes detailed information about the offering terms, underwriting, risk factors, use of proceeds, and company business overview. This type of document is a prospectus supplement used in securities offerings to provide investors with detailed information about the offering and the company. It is not a financial report, earnings release, or management discussion, nor is it an announcement of a report. It is a capital markets document related to fundraising and issuance of shares. Therefore, the appropriate classification is 'Capital/Financing Update' (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, supporting a high confidence in classification.
2013-04-30 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 29, 2013, reporting the entry into a material definitive agreement related to an underwritten public offering of common stock by NeoStem, Inc. It details the terms of the underwriting agreement, the use of proceeds, and includes exhibits such as the underwriting agreement and legal opinion. The content focuses on a financing transaction and capital raising activity. There are no financial statements or earnings data presented, nor is it an announcement of a report publication or a regulatory certification. The primary subject is the company's capital raising through a public offering, which fits the category of Capital/Financing Update.
2013-04-30 English
FORM 424B5
Capital/Financing Update Classification · 100% confidence The document is a Preliminary Prospectus Supplement filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. It relates to an offering of common stock shares by the company NeoStem, Inc. The text includes detailed information about the offering terms, underwriting, risk factors, use of proceeds, and company background. This type of document is a prospectus supplement used in capital raising activities to provide investors with updated and specific information about a securities offering. It is not a financial report, earnings release, or regulatory filing unrelated to capital raising. Therefore, the document fits the category of Capital/Financing Update, which covers updates on company fundraising and financing activities.
2013-04-29 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes preliminary financial results for the quarter ended March 31, 2013, but explicitly states that these are estimates and that full financial statements have not been completed. It also includes announcements of a new services agreement and an intention to offer shares in a public offering. The document does not contain full financial statements or detailed financial analysis, but rather preliminary results and event announcements. Therefore, it is not an Interim/Quarterly Report (IR) or Annual Report (10-K). It is a current report announcing financial results and other material events, fitting the category of Regulatory Filings (RNS). The document length is about 5505 characters, which is consistent with a typical 8-K filing. Hence, the best classification is Regulatory Filings (RNS).
2013-04-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.